Fifty-five patients suffering from acute cerebral ischaemia were treated with pentosan polysulphate (SP54) intravenously and subsequently orally. The control group consisting of 35 patients received the infusion solution and vasodilator drugs. The statistically significant changes appearing following infusion of SP54 include the following parameters: haematocrit, blood viscosity and cholesterol concentrations. In individual cases the euglobulin lysis time was shortened within two hours after the beginning of the infusion. As demonstrated by the statistically reliable results in patients treated with SP54 the neurological symptoms improved significantly within the first two weeks after the onset of the disease compared to the control groups. Based on case reports, recommendations are given for the indication and contraindication of SP54 treatment in cerebral ischaemia.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Third national surgical consensus conference of the Italian Association of Breast Surgeons (ANISC) on management after neoadjuvant chemotherapy: The difficulty in reaching a consensus.
Eur J Surg Oncol
July 2024
Breast Center, San Giovanni-Addolorata Hospital, Via Dell'Amba Aradam 8, 00184, Rome, Italy.
Article Synopsis
- Neoadjuvant chemotherapy (NAC) significantly affects breast cancer surgery, leading to a national Consensus Conference by the Italian Association of Breast Surgeons (ANISC) involving various specialists.
- In November 2022, 164 specialists from 74 Breast Centers participated in an online conference to vote on eleven controversial NAC-related issues, achieving consensus on only three.
- The results showed a general agreement on assessing tumor response via MRI, reassessing biological factors of residual tumors, and possibly skipping formal axillary node dissection for certain patients, highlighting the variability in surgical practices post-NAC.
The Network That Unites a Qualitative Study on Clinical Psychological Intervention for Women with a History of Breast Cancer and Chronic Pain.
Eur J Investig Health Psychol Educ
June 2022
Department of Education, University of Catania, 2 Ofelia, 95124 Catania, Italy.
The aim of this qualitative research is to deepen the knowledge in the field of psycho-oncology and the consequences of chronic and persistent pain by listening to patients' experiences, their emotions and difficulties in facing this hard condition, and assessing their perception of the role of the psychologist in pain management. In this qualitative study, a semistructured interview was used, designed from three research questions: chronic pain and quality of life; chronic pain and psychological well-being; and the role and perception of the psychologist in pain management. The sample consists of 29 women who suffered or have recovered from breast carcinoma, and who currently report having chronic pain due either to the presence of the cancer or as a result of surgery or treatment.
View Article and Find Full Text PDFRibociclib efficacy in special populations and analysis of patient-reported outcomes in the MONALEESA trials.
Expert Rev Anticancer Ther
April 2022
Department of Clinical and Experimental Medicine, University of Catania, Piazza Università, 2 - 95131, Catania, Italy.
Introduction: Cyclin-dependent kinase 4/6 (CDK4/6) inhibitors abemaciclib, palbociclib, and ribociclib radically modified the treatment of hormone receptor-positive/human epidermal growth factor 2-negative advanced breast cancer. Ribociclib efficacy was proved in the phase III MONALEESA-2, -3, and -7 trials. In the first-line setting, ribociclib plus endocrine therapy determined statistically significant improvements in progression-free (PFS) and overall survival (OS) in pre-menopausal (MONALEESA-7) and post-menopausal (MONALEESA-2) women.
View Article and Find Full Text PDFThe effect of probiotic supplementation on the risk of gestational diabetes mellitus among high-risk pregnant women: A parallel double-blind, randomized, placebo-controlled clinical trial.
Biomed Pharmacother
September 2021
Department of Community Nutrition, School of Nutrition and Food Science, Food Security Research Center, Isfahan University of Medical Sciences, Isfahan, Iran. Electronic address:
Background: Based on a comprehensive search, we realized that the findings of the available literature are contradictory, and also limited data are available on Middle Eastern populations in terms of probiotic supplementation during the pregnancy. Therefore, the current double-blind, randomized, placebo-controlled clinical trial was carried out to investigate the effects of probiotic supplementation during pregnancy on the risk of gestational diabetes mellitus and also other maternal and neonatal outcomes.
Materials And Methods: The pregnant women were randomized to either received probiotic supplement (n = 271) or placebo (n = 271) from the first half of the second trimester (14 weeks of pregnancy) up to 24 weeks when pregnant women routinely evaluated regarding the GDM.
Bispecific T-Cell Engager (BiTE) Antibody Construct Blinatumomab for the Treatment of Patients With Relapsed/Refractory Non-Hodgkin Lymphoma: Final Results From a Phase I Study.
J Clin Oncol
April 2016
Maria-Elisabeth Goebeler, Stefan Knop, Max S. Topp, Hermann Einsele, and Ralf C. Bargou, Comprehensive Cancer Center Mainfranken, University of Würzburg, Würzburg; Andreas Viardot, University Ulm; Peter Kufer, Gerhard Zugmaier, Matthias Klinger, Andreas Wolf, Margit Schmidt, and Patrick A. Baeuerle, Amgen Research (Munich); Brigitte Dorsch, Metronomia Clinical Research, Munich; Richard Noppeney, University of Essen Medical Center, Essen; Georg Hess, Johannes Gutenberg-University, Mainz; Stefan Kallert and Andreas Mackensen, University of Erlangen Medical Center, Erlangen; Kathrin Rupertus and Lothar Kanz, University of Tübingen Medical Center, Tübingen; Martin Libicher, Diakoniekrankenhaus Schwäbisch-Hall, Schwäbisch-Hall; Jürgen Scheele, University of Freiburg Medical Center; Eugen Leo, LEOConsulting, Freiburg, Germany; and Dirk Nagorsen and Beate D. Quednau, Amgen, Thousand Oaks, CA.
Article Synopsis
- Blinatumomab is a bispecific T-cell engager used to treat relapsed or refractory B-cell non-Hodgkin lymphoma by targeting CD19 and CD3 antigens.
- A phase I study assessed the maximum tolerated dose (MTD) and side effects of continuous blinatumomab infusion in 76 heavily pretreated patients, leading to an MTD of 60 μg/m²/day due to neurologic events.
- The overall response rate among patients at the MTD reached 69%, with a median response duration of 404 days, indicating promising efficacy for this immunotherapy approach.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!